Article
The amino acid transporter SLC7A5 is required for efficient growth of KRAS-mutant colorectal cancer.
Nature genetics - 1 Jan 2021
Najumudeen Arafath K, Ceteci Fatih, Fey Sigrid K, Hamm Gregory, Steven Rory T, Hall Holly, Nikula Chelsea J, Dexter Alex, Murta Teresa, Race Alan M, Sumpton David, Vlahov Nikola, Gay David M, Knight John R P, Jackstadt Rene, Leach Joshua D G, Ridgway Rachel A, Johnson Emma R, Nixon Colin, Hedley Ann, Gilroy Kathryn, Clark William, Malla Sudhir B, Dunne Philip D, Rodriguez-Blanco Giovanny, Critchlow Susan E, Mrowinska Agata, Malviya Gaurav, Solovyev Dmitry, Brown Gavin, Lewis David Y, Mackay Gillian M, Strathdee Douglas, Tardito Saverio, Gottlieb Eyal, Takats Zoltan, Barry Simon T, Goodwin Richard J A, Bunch Josephine, Bushell Martin, Campbell Andrew D, Sansom Owen J
Abstract excerpt
Oncogenic KRAS mutations and inactivation of the APC tumor suppressor co-occur in colorectal cancer (CRC). Despite efforts to target mutant KRAS directly, most therapeutic approaches focus on downstream pathways, albeit with limited efficacy. Moreover, mutant KRAS alters the basal metabolism of cancer cells, increasing glutamine utilization to support proliferation. We show that concomitant mutation of Apc and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.